Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study

• Published in: JHEP reports Vol. 5; no. 3; p. 100650
• Main Authors: Maasoumy, Benjamin, Ingiliz, Patrick, Spinner, Christoph D., Cordes, Christiane, Stellbrink, Hans-Jürgen, Schulze zur Wiesch, Julian, Schneeweiß, Stephan M., Deterding, Katja, Müller, Tobias, Kahlhöfer, Julia, Dörge, Petra, von Karpowitz, Maria, Manns, Michael P., Wedemeyer, Heiner, Cornberg, Markus
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2023; Elsevier
• Subjects: acute HCV infection; direct-acting antivirals; hepatitis C elimination; recently acquired infection; PP; LLOQ; recently acquired infection; ULN; acute HCV infection; ITT; ALT; HCV; hepatitis C elimination; direct-acting antivirals; SVR; ALT, alanine aminotransferase; ITT, intention-to-treat; ULN, upper limit of normal; HCV, hepatitis C virus; PP, per protocol; LLOQ, lower limit of quantification; SVR, sustained virologic response
• ISSN: 2589-5559; 2589-5559
• DOI: 10.1016/j.jhepr.2022.100650

EASL guidelines recommend 8 weeks of treatment with sofosbuvir plus velpatasvir (SOF/VEL) for the treatment of acute or recently acquired HCV infection, but only 6- and 12-week data are available. Therefore, the aim of this study was to evaluate the safety and efficacy of a shortened 8-week SOF/VEL treatment for acute HCV monoinfection. In this investigator-initiated, prospective, multicentre, single-arm study, we recruited 20 adult patients with acute HCV monoinfection from nine centers in Germany. Patients received SOF/VEL (400/100 mg) as a fixed-dose combination tablet once daily for 8 weeks. The primary efficacy endpoint was the proportion of patients with sustained virological response 12 weeks after the end of treatment (SVR12). The median HCV RNA viral load at baseline was 104,307 IU/ml; the distribution of HCV genotypes was as follows: GT1a/1b/2/3/4: n = 12/1/1/3/3. Thirteen (65%) of the 20 patients were taking medication for HIV pre-exposure prophylaxis. SVR12 was achieved in all patients who complied with the study protocol (n = 18/18 [100%], per protocol analysis), but the primary endpoint was not met in the intention-to-treat analysis (n = 18/20 [90%]) because two patients were lost to follow-up. One serious adverse event (unrelated to study drug) occurred during 12 weeks of post-treatment follow-up. The 8-week treatment with SOF/VEL was well tolerated and highly effective in all adherent patients with acute HCV monoinfection. Early treatment of hepatitis C might effectively prevent the spread of HCV in high-risk groups. NCT03818308. The HepNet acute HCV-V study (NCT03818308), an investigator-initiated, single-arm, multicenter pilot study, demonstrates the efficacy and safety of 8 weeks of daily treatment with the fixed-dose combination sofosbuvir/velpatasvir (400/100 mg) in patients with acute hepatitis C virus (HCV) infection. All patients who completed therapy and were followed-up achieved sustained virologic response. Thus, early treatment with SOF/VEL which might effectively prevent the spread of HCV in high-risk groups can be recommended for patients with acute HCV monoinfection. [Display omitted] •Sofosbuvir/velpatasvir for 8 weeks is effective in patients with acute hepatitis C, even those with high ALT levels.•Treatment of acute hepatitis C with sofosbuvir/velpatasvir was well tolerated.•Availability of a safe and effective treatment for acute HCV infection supports a simplified treatment cascade.